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ABSTRACT  23 
The calcium-sensing receptor (CaSR) is a class C G-protein coupled receptor (GPCR) that detects 24 
extracellular calcium concentrations, and modulates parathyroid hormone secretion and urinary 25 
calcium excretion to maintain calcium homeostasis. The CaSR utilises multiple heterotrimeric G-26 
proteins to mediate signalling effects including: activation of intracellular calcium release; mitogen-27 
activated protein kinase (MAPK) pathways; membrane ruffling; and inhibition of cAMP production. 28 
By studying germline mutations in the CaSR and proteins within its signalling pathway that cause 29 
hyper- and hypocalcaemic disorders, novel mechanisms governing GPCR signalling and trafficking 30 
have been elucidated. This review focusses on two recently described pathways that provide novel 31 
insights into CaSR signalling and trafficking mechanisms. The first, identified by studying a CaSR 32 
gain-of-function mutation that causes autosomal dominant hypocalcaemia (ADH), demonstrated a 33 
structural motif located between the third transmembrane domain and the second extracellular loop of 34 
the CaSR that mediates biased signalling by activating a novel β-arrestin-mediated G-protein-35 
independent pathway. The second, in which the mechanism by which adaptor protein-2 σ-subunit 36 
(AP2σ) mutations cause familial hypocalciuric hypercalcaemia (FHH) was investigated, demonstrated 37 
that AP2σ mutations impair CaSR internalisation and reduce multiple CaSR-mediated signalling 38 
pathways. Furthermore, these studies showed that the CaSR can signal from the cell surface using 39 
multiple G-protein pathways, whilst sustained signalling is mediated only by the Gq/11 pathway. Thus, 40 
studies of FHH and ADH associated mutations have revealed novel steps by which CaSR mediates 41 
signalling and compartmental bias, and these pathways could provide new targets for therapies for 42 
patients with calcaemic disorders.  43 
Page 2 of 28
3 
 
1 Introduction to the CaSR   44 
Extracellular calcium (Ca2+e) is required for diverse biological functions ranging from blood 45 
coagulation, mineralisation of bone matrix, muscle contraction, and hormone secretion (Brown 1991). 46 
Thus, calcium concentrations within the blood are tightly regulated. The parathyroid gland plays an 47 
essential role in calcium homeostasis by detecting Ca2+e in the blood, and in response to 48 
hypocalcaemia, secretes the parathyroid hormone (PTH) to normalize serum calcium concentrations. 49 
PTH achieves this by: enhancing bone resorption; activating calcium reabsorption at the kidneys; and 50 
stimulating the synthesis of 1,25-dihydroxyvitamin D3, which mobilises intestinal calcium absorption 51 
(Fig. 1A) (Riccardi and Brown 2010). The net effect of these three pathways is to increase Ca
2+
e, 52 
which provides feedback inhibition to the parathyroid gland, to suppress PTH secretion (Conigrave 53 
and Ward 2013). The parathyroid is able to detect Ca
2+
e concentrations in the blood using the cell-54 
surface expressed calcium-sensing receptor (CaSR), a class C G-protein coupled receptor (GPCR), for 55 
which Ca2+ is the major ligand (Conigrave and Ward 2013; Riccardi and Brown 2010). 56 
The CaSR is a 1078 amino acid protein that exists at cell surfaces as a disulphide-linked homodimer 57 
(Ward, et al. 1998), although it is capable of forming heterodimers (Chang, et al. 2007; Gama, et al. 58 
2001). The CaSR has a large extracellular domain, which was recently crystallized by two 59 
independent labs, and consists of a bilobed venus fly-trap ligand binding domain (VFTD), and a 60 
cysteine-rich domain (CRD) (Geng, et al. 2016; Zhang, et al. 2016) (Fig. 1B). Ca2+e binds between the 61 
two lobes (lobe 1 and lobe 2) of the VFTD, which initiates a conformational change, facilitating lobe 62 
2-lobe 2 dimerisation and allowing the cysteine-rich domains to interact (Geng et al. 2016; Zhang et 63 
al. 2016). These conformational changes are predicted to re-orientate the seven transmembrane (TM) 64 
domain (Geng et al. 2016), and consequently activate the associated G-proteins and initiate signal 65 
transduction (Standfuss, et al. 2011). The CaSR has been reported to couple to multiple G-protein 66 
subtypes, but predominantly signals by: the Gi/o pathway, to suppress cAMP and activate mitogen-67 
activated protein kinase (MAPK) cascades (Kifor, et al. 2001; Thomsen, et al. 2012); the Gq/11-68 
phospholipase C (PLC)-mediated pathway, to generate inositol 1,4,5-trisphosphate (IP3) and 69 
diacylglycerol, that activate intracellular calcium (Ca2+i) mobilisations (Hofer and Brown 2003) and 70 
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MAPK pathways, respectively. The CaSR can also couple to a G-protein-independent mechanism 71 
involving β-arrestin proteins to also activate MAPK signalling (Thomsen et al. 2012) (Fig. 2).  72 
 73 
2 Human disorders of the CaSR provide insights into receptor signalling mechanisms 74 
The importance of the CaSR in the regulation of Ca2+e is highlighted in patients with germline 75 
mutations of the receptor that have disorders of calcium homeostasis. Heterozygous loss-of-function 76 
mutations in the CaSR lead to the autosomal dominant condition familial hypocalciuric 77 
hypercalcaemia (FHH) (Pollak, et al. 1993), which is characterised by lifelong mild-to-moderate 78 
hypercalcaemia, normal or mildly raised serum PTH levels and low urinary calcium excretion (Firek, 79 
et al. 1991; Marx 2015). FHH is considered to be a benign disorder as most patients are 80 
asymptomatic, but it can be associated with chondrocalcinosis and pancreatitis in some cases (Hannan 81 
and Thakker 2013; Pearce, et al. 1996a; Volpe, et al. 2009). Homozygous and compound 82 
heterozygous loss-of-function mutations of the CaSR are the common cause of neonatal severe 83 
hyperparathyroidism (NSHPT), which is characterised by marked elevations in serum calcium and 84 
PTH, failure to thrive and hyperparathyroid bone disease (Chattopadhyay and Brown 2006; Hannan 85 
and Thakker 2013; Pollak et al. 1993). On occasion, heterozygous CaSR mutations may lead to an 86 
NSHPT-like phenotype, and this is largely due to the dominant-negative nature of the mutant receptor 87 
on the wild-type CaSR in these cases (Obermannova, et al. 2009; Pearce, et al. 1995). 88 
Gain-of-function mutations of the CaSR cause autosomal dominant hypocalcaemia (ADH) 89 
characterised by mild-to-moderate hypocalcaemia and inappropriately low or normal PTH 90 
concentrations (Hannan and Thakker 2013; Pearce, et al. 1996b). Up to 50% of patients present with 91 
hypocalcaemic symptoms of paraesthesia, carpopedal spasms, seizures, and ectopic calcification of 92 
the kidneys and basal ganglia (Hannan and Thakker 2013; Pearce et al. 1996b). Some patients with 93 
gain-of-function mutations in CaSR may have Bartter syndrome type 5, which is characterised by 94 
renal salt wasting, hypokalaemia, hyperreninaemia and hyperaldosteronaemia (Vargas-Poussou, et al. 95 
2002; Watanabe, et al. 2002).  96 
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2.1 Biased signalling of the CaSR  97 
Functional studies in HEK293 cells have demonstrated that disease-causing mutations may influence 98 
CaSR signalling responses in a biased manner (Leach, et al. 2012). Despite the capability of the CaSR 99 
to signal via multiple signalling pathways, in vitro studies in HEK293 cells have shown that it 100 
preferentially couples to the Ca2+i signalling pathway (Leach et al. 2012). In contrast, disease-causing 101 
CaSR mutants have been shown to switch this preferential signalling, with some FHH1-causing 102 
mutations signalling equally via the Ca2+i and MAPK pathways, or predominantly via MAPK 103 
pathways; while many ADH1-associated mutants couple more strongly to Ca
2+
i (Leach et al. 2012). 104 
Furthermore, studies of positive and negative allosteric CaSR modulating compounds, revealed they 105 
too can mediate a biased signalling response, with both classes of drugs influencing Ca2+i to a greater 106 
extent than ERK1/2 phosphorylation (Leach, et al. 2013). Thus, these findings established that 107 
agonist-induced CaSR signalling may occur in a biased manner, although the GPCR structural motifs 108 
mediating ligand-dependent bias were not described.  109 
 110 
2.2  Novel insights into mechanisms by which CaSR can mediate signalling bias 111 
Recently, a novel ADH1-associated CaSR mutation, Arg680Gly, has provided some insights into the 112 
molecular mechanisms mediating signalling bias (Gorvin, et al. 2018a). In vitro analyses showed that 113 
Ca2+i signalling in cells expressing the Arg680Gly mutation was not different to that observed in wild-114 
type cells, in contrast to previously reported ADH1-associated CaSR mutants (Gorvin et al. 2018a). 115 
However, the Arg680Gly mutation did enhance MAPK signalling (Gorvin et al. 2018a). Furthermore, 116 
this type of signalling bias, in which an ADH1 mutation enhances MAPK signalling, but does not 117 
affect Ca2+i has not previously been described and provided an opportunity to explore the role of the 118 
Arg680 residue in CaSR structure-function. As MAPK acts as a convergence pathway for multiple 119 
CaSR signalling pathways (Fig. 2) each was investigated using a single reporter assay measuring 120 
luciferase upstream of a serum-response element (SRE), which acts as a measure for MAPK-mediated 121 
transcription (Gorvin, et al. 2017b). By applying compounds that specifically block either the Gq/11 122 
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((YM-245890 and UBO-QIC), the Gi/o (pertussis toxin) or the β-arrestin (β-arrestin-1 and β-arrestin-2 123 
targeting siRNA) pathways, it was shown that the Arg680Gly mutation enhanced MAPK signalling 124 
by a β-arrestin1/2-mediated pathway (Gorvin et al. 2018a; Schrage, et al. 2015; Takasaki, et al. 2004).  125 
 126 
The structural location of the mutant residue within the CaSR transmembrane domain (TMD) region 127 
provides some insights into the likely mechanism mediating this bias. Homology modelling of the 128 
CaSR TMD, based upon the structure of the closely related human metabotropic glutamate receptor 1 129 
(mGluR1) (Gorvin et al. 2018a; Hu, et al. 2005), predicts that the Arg680 residue lies at the 130 
extracellular side of TM3, and that the residue forms salt bridge connections with the side chain of 131 
adjacent residues in extracellular loop 2 (ECL2) (Glu767) or TM7 (Glu837) (Fig. 3). Such 132 
connections between residues within TMDs or with ECLs of GPCRs are known to be important in 133 
receptor activity. For example, TM3 and TM6 of the β2AR forms ionic interactions which lock the 134 
receptor in an inactive state, and conformational changes within these helices governs G-protein 135 
coupling at the cytoplasmic face of the receptor (Ballesteros, et al. 2001; Rasmussen, et al. 2007). 136 
Furthermore, disruption of a salt bridge in β2-AR allows lateral displacement of TM3 away from 137 
TM4 and TM5, facilitating β-arrestin binding (Shukla, et al. 2014), and it was therefore hypothesised 138 
that the CaSR Arg680Gly mutation may break a salt-bridge between TM3 and ECL2 or TM7 139 
allowing β-arrestin to bind more readily at the CaSR cytoplasmic face (Gorvin et al. 2018a). The 140 
importance of the Arg680, Glu767 and Glu837 residues in the CaSR has previously been recognised. 141 
Mutation of Glu767 and Glu837 has been shown to increase signaling by the CaSR (Hu, et al. 2006; 142 
Hu et al. 2005; Hu, et al. 2002; Uckun-Kitapci, et al. 2005), and previous structural homology models 143 
that investigated the binding of allosteric modulator drugs with the CaSR demonstrated that the three 144 
residues form critical contacts for drug binding (Miedlich, et al. 2004; Petrel, et al. 2004), indicating 145 
their importance in CaSR structure-function. To investigate the hypothesis that a salt-bridge is 146 
disrupted by mutation of Arg680, a series of mutations were engineered at the Arg680, Glu767 and 147 
Glu837 residues. First, Glu767 and Glu837 were mutated to Arg residues, to introduce unfavourable 148 
electrostatic interactions. Under these conditions, the Glu767Arg engineered mutant was shown to 149 
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enhance MAPK activity in a similar way to the Arg680Gly ADH1 mutant, a response that was also β-150 
arrestin sensitive (Gorvin et al. 2018a). In contrast, responses in cells expressing the CaSR Glu837Arg 151 
engineered mutant were similar to those in cells expressing WT CaSR (Gorvin et al. 2018a). To 152 
confirm that a salt-bridge is required between residues 680 and 767 in the CaSR, a double mutant was 153 
generated by mutating the Glu767Arg mutant receptor with an additional missense mutation of 154 
Arg680 to Glu680. This should allow the salt-bridge between the two residues to reform. Indeed, in 155 
this double mutant (Glu680-Arg767) CaSR, MAPK signalling was restored to levels similar to those 156 
seen in wild-type cells (Gorvin et al. 2018a).  157 
 158 
Thus, these studies have revealed some of the important structural motifs of CaSR that mediate 159 
signalling bias, and discovery of this novel β-arrestin-specific pathway may help facilitate the 160 
development of targeted therapeutics for CaSR. Furthermore, it demonstrates the importance of 161 
investigating multiple signalling outputs downstream of CaSR, to ensure that potentially disease-162 
causing mutations are not classified as benign polymorphisms (Gorvin et al. 2018a). 163 
 164 
3 Insights from human genetic mutations in components of the CaSR signalling pathway 165 
Both FHH and ADH are genetically heterozygous conditions with mutations in the CaSR accounting 166 
for approximately 65% and 70% of cases, respectively (Hannan, et al. 2012; Nesbit, et al. 2013a). 167 
Two further genetically distinct forms of FHH, and one further distinct form of ADH, have been 168 
described (Mannstadt, et al. 2013; Nesbit et al. 2013a; Nesbit, et al. 2013b). Heterozygous loss- and 169 
gain-of-function germline mutations in the α-subunit of the G-protein 11 (Gα11), a component of the 170 
CaSR signalling pathway, give rise to FHH type-2 (FHH2) and ADH type-2 (ADH2), respectively 171 
(Mannstadt et al. 2013; Nesbit et al. 2013a). Only four FHH2 and six ADH2 mutations have been 172 
described to date, and therefore these mutations account for only a small number of cases of these 173 
disorders (Gorvin, et al. 2016; Gorvin, et al. 2017a; Li, et al. 2014; Mannstadt et al. 2013; Nesbit et al. 174 
2013a; Piret, et al. 2016). FHH type-3 (FHH3) is due to mutations in the sigma subunit of the adaptor 175 
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protein-2 (AP2σ), which plays a fundamental role in clathrin-mediated endocytosis of transmembrane 176 
proteins, such as GPCRs (Nesbit et al. 2013b). The AP2σ protein is ubiquitously expressed and 177 
clathrin-mediated endocytosis is a critical cellular process; however, FHH is a largely benign 178 
condition, and the phenotypes observed in FHH3 patients are largely CaSR-specific. Thus, by 179 
studying the AP2σ mutations identified in FHH3, which have been described in a single residue 180 
(Hannan, et al. 2015; Nesbit et al. 2013b), novel insights into the trafficking and signalling 181 
mechanisms of CaSR have been elucidated, and indicate an important interplay between these two 182 
processes (Gorvin, et al. 2018b).   183 
 184 
3.1  Trafficking of the CaSR 185 
The cell surface expression of the CaSR is important for detecting extracellular ligand and signalling 186 
by the receptor, and therefore the plasma membrane expression of CaSR is carefully regulated. This 187 
involves multiple pathways including: receptor synthesis and secretion, trafficking to the plasma 188 
membrane, and removal of the CaSR from the cell surface by endocytosis.  189 
 190 
3.1.1 Regulation of cell surface expression by functional desensitisation  191 
In contrast to most GPCRs, which undergo agonist-dependent desensitisation by phosphorylation 192 
and/or by β-arrestin proteins, functional desensitisation appears to have only a minimal impact on 193 
CaSR expression, and there are inconsistencies between findings in these studies (Bouschet, et al. 194 
2005; Lorenz, et al. 2007; Pi, et al. 2005; Thomsen et al. 2012). Initial studies of the CaSR showed 195 
that several proteins desensitise the receptor. These include: PKC, which phosphorylates the receptor 196 
following activation of signalling pathways and recruits β-arrestin; G-protein regulatory kinase (GRK) 197 
2, which binds to Gαq and inhibits its signalling; and, GRK4 which phosphorylates CaSR to facilitate 198 
desensitisation (Lorenz et al. 2007; Pi et al. 2005). Furthermore, GRKs and β-arrestin have 199 
independent functions as combined treatment of cells with these proteins enhances desensitisation 200 
(Lorenz et al. 2007). The traditional view of GPCR desensitisation and internalisation was one in 201 
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which the receptor is phosphorylated and β-arrestin recruited, followed by internalisation of the 202 
receptor by clathrin-mediated endocytosis, which is facilitated by interactions between β-arrestin and 203 
AP2 (Shukla, et al. 2011). While studies of CaSR showed that β-arrestin can be recruited, this did not 204 
enhance receptor internalisation, which only occurred when cells were treated with high 205 
concentrations of Ca2+e (10mM) (Lorenz et al. 2007). β-arrestin is also now recognised to have 206 
another function, as a scaffold protein that facilitates signalling either at the plasma membrane, or for 207 
some GPCRs, at the endosome (Shukla et al. 2014). This function of β-arrestin has been recognised 208 
for CaSR in some studies, providing seemingly contradictory information to that in studies of 209 
functional desensitisation. Thus, treatment of cells with dominant-negative forms of β-arrestin1 or β-210 
arrestin2, or with siRNA targeting β-arrestin1 or β-arrestin2, reduces the pERK and membrane 211 
ruffling signals downstream of CaSR (Bouschet et al. 2005; Gorvin et al. 2018b; Thomsen et al. 212 
2012). Further studies are required to determine whether the discrepancies within these data sets are 213 
due to experimental differences, differences in cell type, or if both desensitisation and enhanced 214 
signalling occur downstream of CaSR, but at different spatial or temporal points. 215 
 216 
3.1.2 Regulation of cell surface expression by the secretory pathway and agonist-driven 217 
insertional signalling (ADIS) 218 
The cell surface expression of CaSR, and mechanisms by which the receptor is synthesised and 219 
exported to the plasma membrane, are generally well understood. The CaSR is synthesised at the ER 220 
where it forms homodimers (Pidasheva, et al. 2006) and undergoes quality control and immature 221 
glycosylation steps prior to progression to the Golgi (Fan, et al. 1997). At the Golgi, the CaSR 222 
undergoes further maturation. This forward trafficking through the secretory pathway involves a 223 
number of regulatory proteins that have been well described in previous reviews (Breitwieser 2013; 224 
Huang, et al. 2011). The core-glycosylated CaSR is then retained within pre-plasma membrane 225 
compartments (Fan et al. 1997). Therefore CaSR is retained intracellularly within two large 226 
intracellular reserves: one at the ER and one at pre-plasma membrane compartments (Breitwieser 227 
2012).  228 
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 229 
The large pool of fully mature CaSR plays a unique role in regulation of Ca2+e. Unlike many GPCRs, 230 
the CaSR is chronically exposed to its ligand at baseline concentrations, and thus the receptor 231 
undergoes very little functional desensitisation (Gama and Breitwieser 1998). Furthermore, CaSR is 232 
able to elicit signalling responses for as long as elevated Ca2+e is available (Grant, et al. 2011; Lorenz 233 
et al. 2007; Pi et al. 2005). Experimental studies have sought to explain this apparent paradox and 234 
using a combination of total internal reflection fluorescence microscopy (TIRFm) and a construct that 235 
allows the simultaneous measurement of CaSR insertion within plasma membranes and endocytosis 236 
(known as BSEP-CaSR), a new model for CaSR cell surface expression has emerged (Fig. 4). This 237 
model proposes that in the basal state, CaSR is only weakly expressed at the plasma membrane, but 238 
on exposure to increases in Ca
2+
e there is an increase in anterograde trafficking through the secretory 239 
pathway (Grant et al. 2011) (Fig. 4). This increase in the secretory pathway involves both mature 240 
CaSR located in pre-plasma membrane regions, and newly synthesised CaSR from the ER 241 
(Breitwieser 2013; Grant et al. 2011), and at present the mechanisms that trigger the ADIS events are 242 
not fully elucidated. However, studies in which ADIS and CaSR signalling were measured 243 
simultaneously revealed that elevated Ca2+i and the Gαq/11 pathway is likely involved (Gorvin et al. 244 
2018b; Grant, et al. 2012). Furthermore, the 14-3-3 proteins, which bind CaSR at an Arg-rich site 245 
within the C-terminus, limits the release of CaSR from the endoplasmic reticulum, and therefore 246 
regulates CaSR cell surface expression by reducing the ADIS-mobilisable pool of the receptor (Grant, 247 
et al. 2015). The presence of the ADIS system and constitutive endocytosis may also explain some of 248 
the inconsistencies between studies of CaSR trafficking, as endocytosis of the receptor is balanced by 249 
the continual insertion of new CaSR from the secretory pathway (Breitwieser 2013). Those studies in 250 
which a tagged construct and cell surface labelling (e.g. FLAG) was used in isolation, without also 251 
measuring insertion of new CaSR within the plasma membrane, may not reflect the physiological 252 
state. Similarly, measurement of total cell surface expression of receptor cannot be used as a surrogate 253 
for determining the rate of internalisation.  254 
 255 
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These studies have demonstrated that trafficking of the CaSR plays a critical role in receptor 256 
signalling and calcium homeostasis. More recent studies, building upon these initial findings, have 257 
identified further insights into CaSR cell surface expression and endocytosis, and recognised further 258 
connections between the trafficking and signalling of this receptor.   259 
 260 
3.1.3 Regulation of cell surface expression by endocytosis 261 
The CaSR has been described to have two types of internalisation: a constitutive pathway (Grant et al. 262 
2011), and an agonist-driven pathway (Gorvin et al. 2018b; Lorenz et al. 2007). The CaSR was shown 263 
to internalise using clathrin-mediated endocytosis in early studies (Holstein, et al. 2004). In addition, 264 
CaSR has been described to associate with several proteins that facilitate clustering at the plasma 265 
membrane and therefore increase the efficiency of internalisation, or act as scaffolds to enable 266 
signalling to occur. One such protein is caveolin-1, with which CaSR has been shown to 267 
coimmunoprecipitate (Kifor, et al. 1998). CaSR has been described to be enriched in caveolae 268 
structures in parathyroid chief cells and osteosarcoma cells (Jung, et al. 2005; Kifor et al. 1998; Sun 269 
and Murphy 2010). CaSR-mediated signalling is impaired in cells treated with caveolin-1 targeting 270 
siRNA, and it is likely that this signalling function is facilitated by caveolae acting as signalling hubs 271 
allowing the CaSR, G-proteins and PKC to cluster together (Jung et al. 2005; Kifor et al. 1998; Sun 272 
and Murphy 2010). However, it is currently unknown whether caveolin facilitates CaSR clustering 273 
within caveolae structures to enhance signalling, or whether the signalling itself drives this clustering 274 
to encourage endocytosis (Breitwieser 2013). Filamin is an actin binding cytoskeleton protein that is 275 
important for protein scaffolding (Hjalm, et al. 2001) and may also facilitate clustering that aids in 276 
receptor endocytosis. Filamin binds to the CaSR C-terminus and increases total cellular content of 277 
CaSR by preventing its proteosomal degradation (Hjalm et al. 2001), with some studies showing 278 
CaSR expression is reduced in cells treated with siRNA targeted against filamin. However, other 279 
reports show no such changes in CaSR expression, and this likely requires further investigation 280 
(Huang, et al. 2006; Mingione, et al. 2017). The net result of Filamin A binding to CaSR is increased 281 
MAPK signalling by the receptor (Hjalm et al. 2001; Pi, et al. 2002).  282 
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 283 
3.1.4 Effect of AP2σ mutations on CaSR signalling and trafficking 284 
Mutations in AP2σ have been demonstrated to cause FHH3, and are associated with impaired CaSR-285 
mediated Ca2+i signalling (Nesbit et al. 2013b). The AP2 complex is a ubiquitously-expressed 286 
heterotetrameric protein which plays a fundamental role in the clathrin-mediated endocytosis of 287 
transmembrane proteins, such as GPCRs. The two larger subunits, α and β, have appendages that bind 288 
to the clathrin coat proteins, plasma membrane phospholipids, and endocytic accessory proteins (e.g. 289 
β-arrestin); while the two smaller subunits, µ and σ, bind to endocytic motifs of cargo proteins 290 
(Collins, et al. 2002; Jackson, et al. 2010; Kelly, et al. 2008; Kirchhausen, et al. 2014) (Fig. 4). The 291 
AP2µ subunit recognises tyrosine-based motifs and the AP2σ subunit recognises dileucine-based 292 
motifs (Haucke and De Camilli 1999; Kelly et al. 2008) (Fig. 4). FHH3-associated mutations in the 293 
AP2σ protein have been reported to affect the Arg15 residue, and structural modelling studies using a 294 
published structure of the AP2 complex, have shown these missense mutations (to Cys15, His15 and 295 
Leu15) likely disrupt interactions with a putative dileucine motif in the CaSR C-terminus (Nesbit et 296 
al. 2013b), and thus affect CaSR endocytosis. 297 
  298 
Initially this hypothesis was tested using an ELISA assay of total CaSR at cell surfaces in HEK293 299 
cells stably overexpressing CaSR (HEK-CaSR), and transiently transfected with AP2σ-mutant 300 
proteins. This showed that AP2σ-mutant expressing cells had increased CaSR cell surface expression 301 
when compared to AP2σ-WT cells following stimulation with 5mM Ca
2+
e (Nesbit et al. 2013b). Thus, 302 
it was concluded that CaSR endocytosis is impaired in these cells resulting in increased total CaSR 303 
cell surface expression (Nesbit et al. 2013b). More detailed studies characterising the ADIS and 304 
endocytosis components of CaSR regulation in AP2σ mutant cells using TIRFm and the BSEP-CaSR 305 
construct, showed both ADIS and CaSR endocytosis were impaired resulting in the net effect of an 306 
increased total CaSR cell surface expression in cells expressing AP2σ mutant protein compared to 307 
WT cells (Gorvin et al. 2018b). Additional TIRFm studies focussing on CaSR and clathrin 308 
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demonstrated that CaSR and clathrin colocalise at plasma membranes, and that the duration of this 309 
colocalisation is prolonged in AP2σ-mutant expressing cells (Gorvin et al. 2018b). Furthermore, the 310 
vesicles containing both CaSR and clathrin in AP2σ-mutant cells, when compared to WT cells, were 311 
less motile, which is an indication that the vesicles are less likely to result in viable endocytic events 312 
(Gorvin et al. 2018b; Rappoport and Simon 2003). Thus, cells expressing AP2σ-mutant proteins have 313 
delayed recruitment of clathrin, and colocalisation with CaSR is prolonged, resulting in impaired 314 
CaSR endocytosis (Gorvin et al. 2018b).   315 
 316 
The effect of the FHH3-associated AP2σ-mutant proteins on multiple CaSR-mediated signalling 317 
pathways has been characterised in a number of cellular assays in HEK293 cells stable overexpressing 318 
AP2σ WT and mutant proteins and lymphoblastoid cell-lines derived from blood samples from FHH3 319 
patients with the AP2σ-Cys15 mutation (Gorvin et al. 2018b; Nesbit et al. 2013b). These studies 320 
confirmed that AP2σ mutations of the Arg15 residue impair Ca2+i mobilisation, phosphorylated 321 
ERK1/2 (pERK1/2) MAPK signalling, membrane ruffling and suppression of cAMP, and that all of 322 
these pathways occur downstream of Gαq/11 and Gαi/o (Gorvin et al. 2018b; Nesbit et al. 2013b). 323 
Therefore, these studies have shown that AP2σ mutations reduce endocytosis resulting in increased 324 
CaSR cell surface expression, but paradoxically decrease CaSR-mediated signalling (Gorvin et al. 325 
2018b). To explain this paradox, we hypothesised that CaSR may be able to continue signalling from 326 
within the cell (i.e. sustained signalling) (Gorvin et al. 2018b). Such sustained signalling has been 327 
previously reported for some class A (e.g. β2-adrenergic receptor (β2AR), dopamine receptor D1 328 
(DRD1), thyroid-stimulating hormone receptor (TSHR), vasopressin receptor 2 (V2R) and luteinizing 329 
hormone receptor (LHR)), and class B (e.g. parathyroid hormone 1 receptor (PTH1R)) GPCRs 330 
(Calebiro, et al. 2009; Feinstein, et al. 2013; Ferrandon, et al. 2009; Irannejad, et al. 2013; Jean-331 
Alphonse, et al. 2014; Kotowski, et al. 2011). Thus, in cells with the AP2σ mutation, in which there is 332 
impaired endocytosis, the availability of internalised receptors from which sustained signals could 333 
emanate would be reduced and thus the net effect would be impaired overall CaSR-mediated 334 
signalling. To test this hypothesis, a combination of imaging and biochemical analyses, along with 335 
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chemical inhibitors were used in HEK-CaSR, HEK-AP2σ and CRISPR-Cas generated β-arrestin 336 
knockout cells to assess CaSR-mediated MAPK signalling (Gorvin et al. 2018b). To assess sustained 337 
signalling two primary assays were used: 1) assessment of pERK1/2 over 60 minutes following 338 
treatment of cells with a 5 min pulse of 5mM Ca2+e; and 2) analysis of SRE luciferase reporter 339 
responses over 12 hours, following a 5 min pulse of 5mM Ca2+e. Using these methods, MAPK 340 
sustained signals were demonstrated in HEK-CaSR cells, and evidence for an internal, likely 341 
endosomal, source was shown in three ways (Gorvin et al. 2018b) (Fig. 5). First, addition of Dyngo, a 342 
chemical inhibitor of dynamin, which is required for vesicle scission during clathrin-mediated 343 
endocytosis, abolishes sustained signals, whilst rapid plasma membrane mediated signals remain 344 
intact. Loss of this sustained response in Dyngo-treated cells was not due to increased apoptosis or 345 
decreased proliferation, and was unaffected by inhibition of CaSR protein synthesis as the sustained 346 
rise in pERK1/2 was not blocked by tunicamycin, an inhibitor of glycosylation of newly synthesised 347 
CaSR. Second, sustained signals were reduced in cells expressing a dominant-negative Rab5 protein, 348 
which delays maturation of early endosomes and therefore slows clathrin-mediated endocytosis. 349 
Third, reduction or loss of these sustained signals was observed in cells expressing AP2σ mutant 350 
proteins (Fig. 5).  351 
 352 
The G-proteins involved in these sustained signals were also explored as MAPK signalling is a 353 
convergence pathway for multiple CaSR-mediated signalling pathways (Fig. 2). The ability of the 354 
Gαq/11 and Gαi/o pathways to activate CaSR sustained signals was investigated using G-protein 355 
specific inhibitors (UBO-QIC and PTx) and the SRE luciferase reporter assay, which showed that 356 
inhibition of both Gαq/11 and Gαi/o impaired the early, plasma membrane mediated CaSR signal, while 357 
only Gαq/11 was important for the later sustained signal. Furthermore, confocal microscopy confirmed 358 
that Gαq and phosphatidylinositol 4,5-bisphosphate (PIP2), the lipid hydrolysed by PLC, colocalise 359 
with CaSR at plasma membranes and a subpopulation of endosomes (Gorvin et al. 2018b). In 360 
addition, inhibitors of the PLC-DAG-IP3 pathway (U73122, GF-109203X and 2-361 
aminoethoxydiphenyl borate (2-APB), which inhibit PLC, PKC and the IP3-receptor, respectively) 362 
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were shown to reduce sustained pERK1/2 signals, indicating that Gαq/11 and its signalling pathway are 363 
important for CaSR-mediated signalling (Gorvin et al. 2018b). Finally, the effects of the β-arrestin 364 
scaffold proteins, which are important for the sustained endosomal signalling of some GPCRs such as 365 
V2R and PTH1R (Feinstein et al. 2013; Wehbi, et al. 2013), were assessed in HEK-CaSR cells with 366 
deletion of the β-arrestin1 and β-arrestin2 genes. In these cells both pERK and SRE reporter responses 367 
were unaffected by deletion of the β-arrestin proteins (Gorvin et al. 2018b). Thus, the CaSR mediates 368 
some MAPK signals from endosomes using Gαq and PLC, but does not require β-arrestin for this 369 
pathway.   370 
 371 
Conclusions and important lessons for the future (or unanswered questions) 372 
Since the cloning of the CaSR gene 25 years ago (Brown, et al. 1993), many insights have been 373 
gained into the role of the CaSR in calcium homeostasis, and by studying patients with mutations 374 
within this gene we have learnt much about CaSR signalling and trafficking mechanisms. The 375 
discovery that CaSR can signal from within the cell, most likely from an endosomal source, and that 376 
disruption of a specific structural motif can mediate G-protein independent signalling bias opens up 377 
many new avenues of investigation. How do mutations in the CaSR affect these endosomal pathways? 378 
Can drugs that target the CaSR affect these pathways? How are trafficking and signalling of the CaSR 379 
so intimately linked? Future studies investigating these questions will undoubtedly reveal further 380 
complexities into the regulation of CaSR, and could provide mechanisms relevant to other GPCRs. 381 
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Figures 1 
Figure 1 Regulation of extracellular calcium at the parathyroid glands 2 
(A) Schematic illustrating how the parathyroid glands respond to changes in extracellular calcium 3 
concentrations [Ca2+e] in the blood. In the presence of low [Ca
2+
e] in the blood, the parathyroid glands 4 
secrete parathyroid hormone (PTH). PTH binds to PTH receptors at the kidney, resulting in calcium 5 
reabsorption, and activation of 1,25-dihydroxyvitamin D3; which in turn acts upon bone to mediate 6 
calcium release, and the intestine to activate calcium resorption. PTH also acts directly on bone to 7 
activate calcium release. The tissue-specific effects on calcium are shown in the hatched box with an 8 
arrow to indicate that these are increased by low [Ca2+] in the blood. (B) Schematic of the 9 
homodimeric calcium-sensing receptor (CaSR) showing the two protomers (CaSR1 and CaSR2) 10 
within the plasma membrane (PM). The calcium-sensing receptor is expressed highly at the 11 
parathyroid gland and its major function is to detect [Ca2+e] and regulate PTH secretion accordingly. 12 
The CaSR has a large extracellular domain (ECD) comprising the venus flytrap domain (VFTD) that 13 
contains two lobes (lobe 1 and lobe 2), and a cysteine-rich domain (CRD). The CRD connects the 14 
ECD to the 7 transmembrane domains (TMD), and the CaSR has a long cytoplasmic intracellular 15 
domain (ICD). Ionised calcium binds between the two lobes of the VFTD. In the presence of high 16 
calcium the CaSR is activated, leading to changes in its signal transduction and reduced PTH 17 
secretion.   18 
Figure 2 Major signalling pathways of the calcium-sensing receptor (CaSR) 19 
Schematic diagram of the calcium-bound homodimeric CaSR and its major signalling pathways. The 20 
CaSR is expressed at the plasma membrane (PM) where its function is to detect [Ca2+e] in the blood. 21 
The CaSR activates two major signalling pathways: Gq/11 and Gi/o. Activation of the Gq/11 pathway 22 
leads to stimulation of its major effector protein phospholipase C (PLC), which hydrolyses 23 
phosphatidylinositol 4,5-bisphosphate (PIP2) to the second messengers diacylglycerol (DAG) and 24 
inositol trisphosphate (IP3). DAG activates protein kinase C (PKC), and the mitogen-activated protein 25 
kinase (MAPK) signalling pathway. IP3 binds to IP3 receptors at the endoplasmic reticulum (ER), 26 
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which mobilise intracellular calcium (Ca2+i) release into the cytoplasm. This increase in Ca
2+
i can 27 
further activate MAPK signalling. The CaSR also activates Gi/o signalling pathways, which inhibits 28 
adenylate cyclase (AC), resulting in reductions in cAMP and protein kinase A (PKA) activity. This 29 
reduction in PKA relieves the inhibition on MAPK signalling and therefore provides another 30 
activation pathway for MAPK signalling. The net effect of all these signalling pathways is a change in 31 
gene transcription. 32 
Figure 3 Disruption of an Arg680-Glu767 salt-bridge within CaSR mediates signalling 33 
bias by activation of a G-protein independent, β-arrestin pathway 34 
(A) Schematic diagram of a CaSR monomer at the plasma membrane (PM) showing the seven 35 
transmembrane domains (TM1-7) with extracellular loops 1–3 (ECL1–3) and intracellular loops 1–3 36 
(ICL1–3). Arg680 is located at the extracellular end of TM3 and is predicted to form a salt-bridge 37 
with either a Glu767 residue on ECL2 or a Glu837 residue on TM7. (B) Homology model of the 38 
CaSR TM3, TM7 and ECL2 region, reproduced with permission from Gorvin et al, 2018, Science 39 
Signaling (Gorvin et al. 2018a). The homology model is based on the published structure of mGluR1 40 
(Wu, et al. 2014). The Arg680 residue is shown projecting from TM3 and is predicted to form a salt 41 
bridge with Glu767 on ECL2. The Glu837 residue on TM7 lies at a 5.7Å distance from the Arg680 42 
residue, and therefore formation of a salt bridge between Arg680 and Glu837 is less likely, but was 43 
tested as the homology model may not reflect the true state of CaSR.  44 
 45 
Figure 4 Mechanisms by which calcium-sensing receptor (CaSR) expression is regulated 46 
at plasma membranes 47 
Schematic showing trafficking pathways regulating the expression of CaSR at the plasma membrane. 48 
The CaSR is continuously synthesised at the endoplasmic reticulum (ER) and undergoes post-49 
translational modifications at the ER and Golgi, before export to the plasma membrane surface. In 50 
addition to this constitutive anterograde trafficking of the CaSR, an additional export pathway for the 51 
CaSR has been described. This pathway is activated by high [Ca2+]e and has been named the agonist-52 
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driven insertional signalling, or ADIS, pathway. Removal of the CaSR from the cell surface is 53 
regulated by clathrin-mediated endocytosis that requires the heterotetrameric adaptor protein-2 (AP2). 54 
AP2 binds directly to transmembrane proteins using its µ-subunit or σ-subunit. The CaSR has a 55 
putative dileucine motif within its C-terminus with which it is predicted to bind to AP2σ. The α-56 
subunit and β-subunit have large appendages that are important for binding to clathrin coat proteins, 57 
plasma membrane phospholipids, and endocytic accessory proteins. Once internalised within clathrin-58 
coated vesicles, CaSR is targeted to the endosomal-lysosomal system. Experimental evidence 59 
suggests CaSR is degraded at the lysosome, and very little, if any, recycling of the receptor occurs.      60 
Figure 5 The calcium-sensing receptor (CaSR) can activate plasma membrane and 61 
endosomal signalling pathways 62 
Schematic diagram showing the signalling pathways that occur downstream of the CaSR. As 63 
described in Figure 2, CaSR predominantly signals via: the Gq/11 pathway, leading to activation of the 64 
intracellular calcium (Ca2+i) and mitogen-activated protein kinase (MAPK) pathways; and the Gi/o 65 
pathway leading to activation of MAPK and reductions in the cAMP pathways. These pathways are 66 
activated rapidly (within 2-5 minutes), and originate at the plasma membrane. The CaSR can also 67 
signal from an internal location using a Gq/11 pathway. This sustained signal that occurs later than the 68 
plasma membrane signal (from 30 minutes), is sensitive to: global clathrin-mediated endocytosis 69 
blockade (shown experimentally using dyngo); inhibition of CaSR-mediated internalisation 70 
(demonstrated in cells expressing FHH3-associated AP2σ mutants); and maturation of internalised 71 
vesicles to the early endosome (demonstrated experimentally using a dominant-negative (DN) form of 72 
Rab5). Thus, this sustained signal is likely to arise within endosomes.   73 
 74 
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